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The presented work is a continuation of our stud-
ies on the synthesis of new isoxazolopyridine deriva-
tives. The derivatives obtained by our team, namely
isoxazolo[5,4-b]pyridine and isoxazolo[4,5-b]pyri-
dine showed antiproliferative activity (1-3). Based on
a literature review it could be stated that the isoxazo-
lo[5,4-b]pyridine derivatives constitute a broad-spec-
trum group of biologically active compounds. Many
studies have confirmed their anti-inflammatory (4, 5),
hypotensive (6), analgesic (7), antisclerotic (8) anti-
convulsant (9), and psychotropic (10, 11) activity. In
contrast, antimicrobial activity has been observed in
the group of isoxazolopyridine carboxylic derivatives
(12), and sulfonamide derivatives have shown anti-
inflammatory activity (4). Sulfonamides are a group of
compounds that are used as antibacterial (Sulfanil-
amidum derivatives), antidiabetic (Tolbutamidum),
diuretic (Furosemidum), analgesic (Celecoxibum),
anti-inflammatory (Sulfasalazinum) and neuroleptic
(Thiotixenum) drugs. 
Derivatives of the heterocyclic systems with a
sulfonamide moiety, being a subject of research,
exhibited different biological activity: antitumor (4,
13-17), antiparasitic (18), anti-inflammatory (19),
antidiabetic (20, 21), antiallergic (16), neuroleptic
(22) and antibacterial (23-25). The sulfonamide
derivative of indole (Indisulam) (26) and sulfon-
amide pyridine derivative (ABT 51) (27) - cell cycle
inhibitors, in clinical trials have shown antitumor
activity against a broad spectrum of cancer cells,
including those resistant to other conventional
chemotherapy.
Due to the emergence of bacterial resistance to
antibiotics, there is still a need to develop new effec-
tive antibacterial drugs. We were interested to find
whether the new sulfonamide derivatives of isoxa-
zolo[5,4-b]pyridine show antibacterial and antipro-
liferative activity. In the presented paper, the con-
ventional and microwave synthesis of new sulfon-
amide derivatives of isoxazolo[5,4-b]pyridine and
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Melting points were determined with a Boethius
apparatus and are uncorrected. Elemental analyses
were performed on a Perkin Elmer 2400 analyzer
(Waltham, MA, USA), and the results are within ±
0.4% of the theoretical values obtained for the new
compounds. Infrared (IR) spectra were recorded with a
Specord M80 spectrophotometer (Zeiss/Analytic Jena,
Germany) for KBr pellets. Hydrogen-1 NMR (1H
NMR) spectra were recorded with a Bruker Avance
ARX-300 instrument (Bruker Analytic, Karlsruhe,
Germany) using DMSO-d6 or CDCl3 as internal stan-
dards. Chemical shifts are reported in ppm from the
internal tetramethylsilane reference. The progress of
the reaction and the purity of the compounds were
monitored using thin layer chromatography (TLC) on
analytical silica gel plates (Merck F254, Darmstadt,
Germany). Microwave-assisted synthesis was per-
formed in a laboratory microwave RM 800PC reactor
(Plazmatronika, Wroc≥aw, Poland). Water was purified
using an Aquadem SDF-Ion exchanger system (TKA,
Thermo Scientific). All chemicals and reagents for the
synthesis were obtained from Alfa Aeser (Karlsruhe,
Germany), Lancaster Synthesis (Morecambe,








Conventional conditions (general procedure A) 
To a solution of 3-aminoisoxazolo[5,4-b]pyri-
dine (1) (1.35 g, 0.01 mol) (1) in 100 mL of tetrahy-
drofurane, a few drops of anhydrous pyridine and
0.01 mol of the appropriate arylsulfonyl chlorides:
benzene-, 4-bromobenzene-, 4-chlorobenzene-, 4-
methyl- and 4-methoxybenzenesulfonyl chlorides
were added. The reaction mixture was heated under
reflux for 6 h. The solvent was evaporated under
vacuum and the residue obtained was triturated with
water, filtered, dried and crystallized from ethanol.
Microwave conditions (general procedure B) 
To a solution of 3-aminoisoxazolo[5,4-b]pyri-
dine (1) (1.35 g, 0.01 mol) in 100 mL of tetrahydro-
furane, a few drops of anhydrous pyridine and 0.01
mol of the appropriate arylsulfonyl chlorides: ben-
zene-, 4-bromobenzene-, 4-chlorobenzene-, p-
toluene- and 4-methoxybenzenesulfonyl chlorides
were added. The reaction mixture was heated under
reflux while being stirred in the microwave reactor
in an aluminum bath at 60-65OC for 15 min (3 ◊ 5
min with 5 min breaks) at microwave power P = 240
W. The solvent was evaporated under vacuum and
the residue obtained was triturated with water, fil-
tered, dried and crystallized from ethanol.
N-Isoxazolo[5,4-b]pyridin-3-yl-benzenesulfon-
amide (2)
Yield 70% (A), 75% (B); m.p. 188-189OC. IR
(KBr, cm-1): 2900-3300 (NH,CH), 1600, 1580, 1450
(C=C, C=N), 1330, 1160 (SO2); 1H NMR (CDCl3, δ,
ppm): 7.35 (dd, 1H, H-5), 7.52-7.94 (m, 6H, H-4 +
Ph), 8.68 (dd, 1H, H-6), 10.82 (s, br, 1H, NH).
Analysis: calcd. for C12H9N3O3S (275.28): C 52.36, H
3.30, N 15.26%; found: C 52.27, H 3.05, N 15.15%.
4-Bromo-N-isoxazolo[5,4-b]pyridin-3-yl-ben-
zenesulfonamide (3)
Yield 60% (A), 75% (B); m.p. 211-212OC; IR
(KBr, cm-1): 2790ñ3150 (NH, CH), 1610, 1500,
1450 (C=C, C=N), 1350, 1175 (SO2), 1070 (p-
ArBr); 1H NMR (CDCl3, δ, ppm): 7.42 (dd, 1H, H-
5), 7.73ñ7.94 (m, 6H, H-4 + Ph), 8.72 (dd, 1H, H-6),
10.93 (s, br, 1H, NH). Analysis: calcd. for C12H8
BrN3O3S (354.18): C 40.69, H 2.28, N 11.86%;
found: C 40.53, H 2.21, N 11.65%.
4-Chloro-N-isoxazolo[5,4-b]pyridin-3-yl-ben-
zenesulfonamide (4)
Yield 60% (A), 75% (B); m.p. 210ñ212OC; IR
(KBr, cm-1): 3250 (NH, CH), 1610, 1500, 1450
(C=C, C=N), 1350, 1165 (SO2); 1H NMR (CDCl3, δ,
ppm): 7.42 (dd, 1H, H-5), 7.73ñ7.94 (m, 6H, H-4 +
Ph), 8.72 (dd, 1H, H-6), 10.93 (s, br, 1H, NH).
Analysis: calcd. for C12H8ClN3 O3S (309.73): C




Yield 66% (A), 72% (B); m.p. 172ñ174OC; IR
(KBr, cm-1): 3100 (NH, CH), 1600, 1510, 1450
(C=C, C=N), 1310, 1160 (SO2), 780 (CH3); 1H NMR
(CDCl3, δ, ppm): 2.48 (s, 3H, CH3), 7.34 (m, 3H, H-
5 + Ph), 7.77 (m, 3H, H-4 + Ph), 8.67 (dd, 1H, H-6),
10.83 (s, br, 1H, NH). Analysis: calcd. for
C13H11N3O3S (289.31): C 53.97, H 3.83, N 14.52%;
found: C 53.65, H 3.52, N 14.35%.
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N-Isoxazolo[5,4-b]pyridin-3-yl-4-methoxyben-
zenesulfonamide (6)
Yield 63% (A), 76% (B); m.p. 195ñ197OC; IR
(KBr, cm-1): 3150 (NH, CH), 1610, 1500, 1450
(C=C, C=N), 1350, 1170 (SO2), 1270 (ArC-O-C),
780 (CH3); 1H NMR (CDCl3, δ, ppm): 3.91 (s, 3H,
CH3), 6.96 (m, 2H, Ph), 7.37 (dd, 1H, H-5), 7.81 (m,
3H, H-4 + Ph), 8.67 (dd, 1H, H-6), 10.96 (s, br, 1H,
NH). Analysis: calcd. for C13H11N3O4S (305.31): C










Conventional conditions (general procedure A)
To a solution of 3-aminoisoxazolo[5,4-b]pyri-
dine (1) (1.35 g, 0.01 mol) in 100 mL of tetrahydro-
furane, a few drops of anhydrous pyridine and 0.02
mol of the appropriate arylsulfonyl chlorides: ben-
zene-, 4-bromobenzene-, 4-chlorobenzene- and 4-
methylbenzenesulfonyl chlorides were added. The
reaction mixture was heated under reflux for 6 h.
The solvent was evaporated under vacuum and the
residue obtained was triturated with water, filtered,
dried and recrystallized from ethanol.
Microwave conditions (general procedure B) 
To a solution of 3-aminoisoxazolo[5,4-b]pyri-
dine (1) (1.35 g, 0.01 mol) in 100 mL of tetrahydro-
furane, a few drops of anhydrous pyridine and 0.02
mol of the appropriate arylsulfonyl chlorides: ben-
zene-, 4-bromobenzene-, 4-chlorobenzene- and 4-
methylbenzenesulfonyl chlorides were added. The
reaction mixture was heated under reflux while
being stirred in the microwave reactor in an alu-
minum bath at 60-65OC for 15 min (3 ◊ 5 min with
5 min breaks) at microwave power P = 240 W. The
solvent was evaporated under vacuum and the
residue obtained was triturated with water, filtered,
dried and recrystallized from ethanol.
N-(Isoxazolo[5,4-b]pyridin-3-yl-)-N-(phenylsul-
fonyl)benzenesulfonamide (7)
Yield 70% (A), 82% (B); m.p. 189-191OC; IR
(KBr, cm-1): 3100 (NH, CH), 1600, 1500, 1450
(C=C, C=N), 1170 (SO2 N=); 1H NMR (CDCl3, δ,
ppm): 7.36 (m, 3H, H-5 + Ph), 7.52ñ7.94 (m, 6H, H-
4 + Ph), 8.69 (dd, 1H, H-6). Analysis: calcd. for
C18H13N3O5S2 (415.44): C 52.04, H 3.15, N 10.11%;
found: C 52.03, H 3.22, N 10.39%.
4-Bromo-N-[(4-bromophenyl)sulfonyl]-N-(isoxa-
zolo[5,4-b]pyridin-3-yl-)benzenesulfonamide (8)
Yield 62% (A), 70% (B); m.p. 229-230OC; IR
(KBr, cm-1): 3100 (NH, CH), 1600, 1500, 1450
(C=C, C=N), 1170 (SO2N=), 1070 (p-ArBr); 1H
NMR (CDCl3, δ, ppm): 7.41 (dd, 1H, H-5), 7.69-
7.80 (m, 6H, H-4 + Ph), 8.72 (dd, 1H, H-6).
Analysis: calcd. for C18H11Br2 N3 O5S2 (573.23): C




Yield 60% (A), 67% (B); m.p. 208-209OC; IR
(KBr, cm-1): 3120 (NH, CH), 1610, 1500, 1450
(C=C, C=N), 1350, 1170 (SO2N), 1070 (p-ArCl); 1H
NMR (CDCl3, δ, ppm): 6.97 (m, 2H, Ph), 7.38 (dd,
1H, H-5), 7.82 (m, 3H, H-4 + Ph), 8.68 (dd, 1H, H-
6). Analysis: calcd. for C18 H11Cl2N3O5S2 ( 484.33):




Yield 68% (A), 75% (B); m.p. 199-201OC; IR
(KBr, cm-1): 3100 (NH, CH), 1600, 1500, 1450
(C=C, C=N), 1170 (SO2N=), 825 (p-Ar-CH3); 1H
NMR (CDCl3, δ, ppm): 2.48 (s, 3H, CH3), 7.36 (m,
5H, H-5 + Ph), 7.70 (m, 5H, H-4 + Ph), 8.67 (dd,
1H, H-6). Analysis: calcd. for C20H17N3O5S2
(443.49): C 54.17, H 3.86, N 9.47%; found: C 54.10,
H 3.75, N 9.37%.
Synthesis of N-isoxazolo[5,4-b]pyridin-3-ylbenza-
mide (11), 4-bromo-N-isoxazolo[5,4-b]pyridin-3-
ylbenzamide (12) and 4-chloro-N-isoxazolo[5,4-
b]pyridin-3-ylbenzamide (13)
Conventional conditions (general procedure A)
To a solution of 3-aminoisoxazolo[5,4-b]pyri-
dine (1.35 g, 0.01 mol) (1) in tetrahydrofurane (100
mL) a few drops of pyridine and benzoyl chloride or
4-bromobenzoyl chloride or 4-chlorobenzoyl chlo-
ride was added. The reaction mixture was heated
under reflux for 10 h. The solvent was then removed
in vacuum and the residue obtained was triturated
with water, filtered, dried and recrystallized from
ethanol.
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Microwave conditions (general procedure B)
To a solution of 3-aminoisoxazolo[5,4-b]pyri-
dine (1) (1.35 g, 0.01 mol) in tetrahydrofurane (100
mL) a few drops of pyridine and benzoyl chloride or
4-bromobenzoyl chloride or 4-chlorobenzoyl chlo-
ride was added. The reaction mixture was heated
under reflux while being stirred in the microwave
reactor in an aluminum bath at 60-65OC for 15 min.
(3 ◊ 5 min. with 5 min. breaks) at microwave power
P = 240 W. The solvent was removed under reduced
pressure. The residue obtained was triturated with
water, filtered, dried and crystallized from ethanol.
N-Isoxazolo[5,4-b]pyridin-3-ylbenzamide (11)
Yield 70% (A), 75% (B); m.p. 213-214OC; IR
(KBr, cm-1): 2880ñ3100 (NH, CH), 1680, 1560
(NHCO), 1600, 1500, 1450 (C=C, C=N); 1H NMR
(CDCl3, δ, ppm): 6.37 (dd, 1H, H-5), 7.49ñ7.55 (m,
5H, Ph), 8.15 (dd, 1H, H-4), 8.43 (dd, 1H, H-6),
12.40 (s, br, 1H, NH). Analysis: calcd. for
C13H9N3O2 (239.23): C 65.27, H 3.79, N 17.56%;
found: C 65.27, H 3.94, N 17.95%.
4-Bromo-N-isoxazolo[5,4-b]pyridin-3-ylbenza-
mide (12)
Yield 63% (A), 70% (B); m.p. 263-266OC; IR
(KBr, cm-1): 2800ñ3100 (NH, CH), 1670, 1570,
1420 (NHCO), 1620, 1520, 1420 (C=C, C=N),
1065, p-Ar-Br); 1H NMR (CDCl3, δ, ppm): 6.40 (dd,
1H, H-5), 7.66 (dd, 1H, H-4), 7.63ñ7.86 (m, 2H,
Ph), 8.03ñ8.07 (m, 2H, Ph), 8.27 (dd, 1H, H-6),
10.21 (s, br, 1H, NH). Analysis: calcd. for
C13H8BrN3O2 (318.13): C 49.08, H 2.53, N 13.21%;
found: C 48.29, H 2.43, N 12.92%.
4-Chloro-N-isoxazolo[5,4-b]pyridin-3-ylbenza-
mide (13) (1)
Yield 65% (A), 70% (B); m.p. 278-280OC; IR
(KBr, cm-1): 2780ñ3080 (NH,CH), 1680, 1560
(NHCO), 1610, 1500, 1450 (C=C, C=N), 1090 (p-
Ar-Cl). 1H NMR (CDCl3, δ, ppm): 6.48 (dd, 1H, H-
5), 7.60 (dd, 1H, H-4), 7.65ñ7.87 (m, 2H, Ph),
8.05ñ8.09 (m, 2H, Ph), 8.27 (dd, 1H, H-6), 10.20 (s,
br, 1H, NH). Analysis: calcd. for C13H8ClN3O2
(273.68): C 57.05, H 2.95, N 15.35%; found: C
56.94, H 2.95, N 15.12%.
Synthesis of 3-(isoxazolo[5,4-b]pyridin-3-ylcar-
bamoyl)benzenesulfonyl chloride (14), 2-bromo-
5-(isoxazolo[5,4-b]pyridin-3-ylcarbamoyl)ben-
zenesulfonyl chloride (15) and 2-chloro-5-(isoxa-
zolo[5,4-b]pyridin-3-ylcarbamoyl)benzenesul-
fonyl chloride (16)
Conventional conditions (general procedure A)
N-Isoxazolo[5,4-b]pyridin-3-ylbenzamide (11)
or 4-bromo-N-isoxazolo[5,4-b]pyridine-3-ylbenza-
mide (12) or 4-chloro-N-isoxazolo[5,4-b]pyridine-3-
ylbenzamide (13) (0.01 mol) was taken in a two-
necked flask with a dropping funnel and reflux con-
denser with CaCl2 guard tube. Chlorosulfonic acid
(0.01 mol) was added through a dropping funnel in a
small portion with occasional shaking. The reaction
mixture was heated in a water bath for 1 h, cooled
and poured onto crushed ice. The separated solid was
filtered off, washed with water, dried, and the crude





mide (18) and 4-chloro-3-[(3-trifluoromethyl-
phenyl)sulfamoyl]-N-isoxazolo[5,4-b]pyridine-3-
yl)benzamide (19)
Conventional conditions (general procedure)
To a mixture of the appropriate sulfonyl chlo-
rides: 3-(isoxazolo[5,4-b]pyridin-3-ylcarbamoyl)ben-
zenesulfonyl chloride (14), 2-bromo-5-(isoxazo-
lo[5,4-b]pyridin-3-ylcarbamoyl)benzenesulfonyl
chloride (15) and 2-chloro-5-(isoxazolo[5,4-
b]pyridin-3-ylcarbamoyl)benzenesulfonyl chloride
(16) in DMF and equimolar amounts of the appro-
priate aromatic amines: 3-methoxy-, 4-methoxy- or
3-(trifluoromethyl)aniline were added. The mixture
reaction was stirred for about 3-5 h and heated under
reflux for 1 h. The solvent was removed under
reduced pressure and the residue was triturated with
water and filtered. The obtained solid was dried and
crystallized from ethanol. 
4-Bromo-3-[(3-methoxyphenyl)sulfamoyl]-N-
isoxazolo[5,4-b]pyridin-3-yl)benzamide (17)
Yield 59%; m.p. 279-281OC; IR (KBr, cm-1):
2700ñ3100 (NH, CH), 1670, 1570 (NHCO), 1620,
1530, 1400 (C=C, C=N), 1380, 1140 (SO2NH),
1240 (C-O-C), 1070 (p-Ar-Br). 1H NMR (CDCl3, δ,
ppm): 3.91 (s, 3H, CH3), 6.40 (dd, 1H, H-5), 7.65
(dd, 1H, H-4), 7.83ñ8.08 (m, 7H, 2◊Ph), 8.28 (dd,
1H, H-6), 10.21 (s, br, 1H, NH), 12.22 (s, 1H, NH).
Analysis: calcd. for C20H15BrN4O5S (503.33): C




Yield 65%; m.p. 269-271OC; IR (KBr, cm-1):
2900ñ3100 (NH, CH), 1670, 1570 (NHCO), 1620,
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1520, 1400 (C=C, C=N), 1380, 1140 (SO2NH),
1240 (C-O-C), 1070 (p-Ar-Br). 1H NMR (DMSO-d6,
δ, ppm): 3.91 (s, 3H, CH3), 6.41 (dd, 1H, H-5), 7.65
(dd, 1H, H-4), 7.83ñ8.03 (m, 7H, 2◊Ph), 8.30 (dd,
1H, H-6), 10.20 (s, br, 1H, NH), 12.21 (s, 1H, NH).
Analysis: calcd. for C20H15BrN4O5S (503.33): C





Yield 70%; m.p. 259-261OC; IR (KBr, cm-1):
3100 (NH, CH), 1670, 1570 (NHCO), 1620, 1520,
1400 (C=C, C=N), 1380, 1140 (SO2NH), 1090 (p-
Ar-Cl). 1H NMR (DMSO-d6, δ, ppm): 6.42 (dd, 1H,
H-5), 7.67 (dd, 1H, H-4), 7.84ñ8.00 (m, 7H, 2◊Ph),
8.30 (dd, 1H, H-6), 10.20 (s, br, 1H, NH), 12.20 (s,
1H, NH). Analysis: calcd. for C20H12Cl F3N4O4S
(496.85): C 48.35, H 2.43, N 11.28%; found: C
48.25, H 2.35, N 11.26%.
Biology
In vitro antibacterial activity
Antibacterial activity was tested against four
strains: Escherichia coli (ATCC 25922), Staphylo-
coccus aureus (ATCC 25923), Pseudomonas aerug-
inosa (ATCC 27853), Bacillus subtilis (ATCC
6033) and two clinical isolates: Salmonella enterica
and Klebsiella pneumoniae. All bacterial strains
were obtained from the Polish Collection of
Microorganisms (PCM). Screening tests were per-
formed by the disc diffusion method on Mueller-
Hinton agar, according to the recommendations of
the Clinical and Laboratory Standards Institute (29),
with sulfanilamide and sulfadiazine as references.
Tested compounds were dissolved in DMSO and
applied on Whatman GF/F glass microfibre 5 mm
sterile disks. The size of the inhibition zone was
determined after 20 h of incubation at 37OC.
MIC (minimum inhibitory concentration) val-
ues were determined for strain selected in the
screening test using the serial dilutions method with
rezazurine as a marker of bacterial growth (30). 
In vitro cytotoxicity
Toxicity of compounds 2 and 5 was tested
using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) proliferation assay on
breast cancer cell line (MCF7). Levofloxacin was
used as a reference. 
RRSULTS AND DISCUSSION 
Chemistry
The synthesis of the new sulfonamide deriva-
tives of isoxazolo[5,4-b]pyridine is presented in
Figure 1. In the first step, 3-aminoisoxazolo[5,4-
b]pyridine (1) (1) was subjected to arylsulfonation
reaction using selected arylsulfonyl chlorides: ben-
zenesulfonyl, 4-bromo-, 4-chloro-, 4-methyl- and 4-
metoxybenzenesulfonyl chloride in tetrahydrofuran
in the presence of a catalytic amount of anhydrous
pyridine. As a result of these condensation reactions,
appropriately substituted phenyl-, 4-chloro-, 4-
bromo-, 4-methyl- and N-isoxazolo[5,4-b]pyridin-
3-yl-4-methoxybenzenesulfonamides (2-6) were
obtained. Reactions were carried out in a conven-
tional way through 6 h heating in a heating mantle.
For comparison, the reaction mixtures were heated
in a Plazmatronika RM 800 microwave reactor at
60-65O C in 3 cycles for 5 min with 5 min intervals
using microwave power of P = 240 W.
The heating time for the reaction mixtures in
the microwave reactor was much shorter compared
to the heating in the heating mantle. Reaction yield
was higher by 35% on average when microwave
radiation was applied. The structures of the obtained
new derivatives were determined by elemental
analysis and spectral spectra. In the IR spectra of 2-
6 derivatives two characteristic absorption bands of
secondary sulfonamide moiety in the range between
1160 and 1350 cm-1 were observed. In the IR spec-
trum for the N-isoxazolo[5,4-b]pyridin-3-yl-4-
Table 1. Bacterial strains used in this work.
Bacteria PCM number ATCC number
1. Escherichia coli PCM 2057 ATCC 25922
2. Staphylococcus aeureus PCM 2054 ATCC 25923
3. Pseudomonas aeruginosa PCM 2058 ATCC 27853
4. Bacillus subtilis PCM 2021 ATCC 6033
5. Salmonella enterica PCM 2565 ATCC 13311
6. Klebsiella pneumonie clinical strain
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methoxybenzenesulfonamide (6) an absorption band
representing an ether moiety at 1270 cm-1 is also
observed.
In the 1H NMR spectra of compounds 2-6, sig-
nals of aromatic protons of pyridine and phenyl ring
are observed in the range of δ = 7.3-8.6 ppm. In the
field of low intensity, single signals at δ = 10.8 ppm
corresponding to the NH proton of ñSO2NH- moiety
are present. For comparison, the abovementioned
reactions were carried out via a two-stage process.
After a quick heating of the reaction mixture in a
heating mantle, in order to dissolve the reactants in
the solvent, further heating was performed in a
microwave reactor at 50-60OC in three cycles for 3
min with 5 min. intervals. The applied microwave
power was P = 160 W. The resulting reaction yields
were higher by 5% on average compared to yields
obtained via a one-stage method.
However, after adaptation of the excess of
selected aryl sulfonyl chlorides in the above reac-
tions disulfonamides isoxazolo[5,4-b]pyridine 7-10
derivatives presented in Figure 1 were extracted. In
the IR spectra of these compounds, an intense
absorption bands at 1170  cm-1 characteristic for the
secondary sulfonamides moiety (= NSO2-) were
observed.
In the second stage of the study, 3-aminoisox-
azolo[5,4-b]pyridine (1) was the substrate for the
synthesis of 4-bromo-, 4-chloro-N-(isoxazolo[5,4-
b]pyridin-3-yl)benzamide and N-(isoxazolo[5,4-
b]pyridin-3-yl)benzamide 11-13, which were previ-
ously obtained using the classical method (1), and
for comparison their syntheses were also done using
the microwave method.
Subsequently, the obtained amides 11-13 were
subjected to sulfonation reaction with sulfonic acid
yielding the appropriate sulfochlorides 14-16. The
extracted sulfochlorides were subjected to amonoly-
sis with selected amines: 3- and 4-methoxyaniline
and 3-trifluoromethylaniline, in the presence of cat-
alytic amount of triethylamine yielding the appro-
priate sulfonamide derivatives presented as struc-
tures 17-19. In the IR spectra of the compounds two
characteristic absorption bands for sulfonamides are
observed at 1160 and 1370 cm-1. However, in the
spectra of compounds 17-19, except for signals from
aromatic protons in the range of δ = 6.5-8.5 ppm,
additional signals of the phenyl rings appeared in the
range of δ = 7.5-8.24 ppm. In the spectra of com-
pounds 17-18, in the magnetic field of high intensi-
ty, at δ = 3.9 ppm signals of the methoxy protons are
observed.
Antibacterial activity 
In order to assess the activity of the synthe-
sized compounds, series of disk diffusion test were
performed. The assays were performed as described
in the material and methods section, with four strain
types. In the first test, all compounds were adminis-
tered at a dose of 500 µg per disc. In the case of
compounds 17 and 18 doses were reduced to 440 µg
and 250 µg, respectively. Reduced doses were
caused by poor solubility. For strains which showed
sensitivity to the tested compound, doses in the
range from 20 to 250 µg/disc were examined, and
all tests were done in triplicate. Surprisingly, com-
pounds 2 and 5 inhibit the growth of strains of P.
aeruginosa and E. coli. A dose of 500 µg/disc of 2
gave the inhibition zone of 31 mm 5 of 32 mm on
P. aeruginosa plate and 22 mm for both compounds
on the E. coli plate. Lower doses gave smaller inhi-
bition zones. All results are summarized in Table 2.
Table 2. The antimicrobial activity of isoxazole derivatives[5,4-b]pyridines. 
dose E. coli P. aeruginosa B. subtilis S. aureusCompound
[µg/disc] d [mm] d [mm] d [mm] d [mm]
2
500 22 31 no activity no activity
250 6 13 not tested not tested
3 500 no activity no activity no activity no activity
5
500 22 32 no activity no activity
250 6 14 not tested not tested
6 500 no activity no activity no activity no activity
17 250 no activity no activity no activity no activity
18 440 no activity no activity no activity no activity
Sulfanilamide 500 no activity no activity 25 no activity
Sulfadiazine  500 14 no activity  22 12
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Administration of 125 µg on disc caused a 6 mm
slower growth zone on the P. aeruginosa plate.
Because the effect on the growth of E. coli was vis-
ible but explicitly weaker, we also tested other
Enterobacteriaceae bacteria: Salmonella enterica
and Klebsiella pneumoniae, but we did not observe
any inhibition of growth (data not shown). We also
determined a minimal inhibitory concentration
(MIC) for 2 and 5 in tests against P. aeruginosa.
The values obtained are 2 ñ 47 µg/mL, 5 ñ 44
µg/mL. 
As shown, the tested compounds 2 and 5 are
characterized by antibacterial activity against
Gram-negative bacteria Escherichia coli and
Pseudomonas aeruginosa, do not show such activi-
ty against representatives of Gram-positive bacteria
Bacillus subtilis and Staphylococcus aureus, and
interestingly, are inactive against other tested
Gram-negative bacteria Salmonella enterica and
Klebsiella pneumoniae. Such differences in activity
against bacteria of the same taxonomic family indi-
cate a high specificity of these compounds against
the bacteria Pseudomonas. A number of antibacter-
ial compounds specific against Gram-positive bac-
teria is known while there are few factors that selec-
tively inhibit the growth of Gram-negative bacteria.
In medicine, particularly valuable compounds
specifically inhibit bacterial narrow taxon and do
not affect the species closely related. Comparison
of the effects of all the tested antimicrobial com-
pounds allow to suspect that a key problem limiting
the activity of the resulting compounds is the solu-
bility. Further studies are needed to explain the
mechanism of action and base of the compound
specificity.
MTT cytotoxicity activity
Levofloxacin has proven anti-Pseudomonas
activity and is administered as a drug of choice in
humans; its cellular toxicity must therefore be negli-
gible in the human cell line. With the antibacterial
activity of 2 and 5 and their potential use in phar-
maceutical practice shown in this work, it was nec-
essary to demonstrate that they also lack any sub-
stantial cellular toxicity in humans. Here we show
that after 48 h of incubation, the IC50 of 2 was
190.67 µg/mL; 5 ñ 163.35 µg/mL while levo-
floxacin showed IC50 at 131.9 µg/mL in the MCF7
cell line. After 72 h of incubation, the IC50 of 2 was
152.56 µg/mL, 5 - 161.08 µg/mL, while IC50 of levo-
floxacin was at the level of 114.92 µg/mL. Both test-
ed compounds showed even lower antiproliferative
activity in the MCF7 cell line than the levofloxacin
control.
CONCLUSIONS
The use of microwave radiation in conducted
syntheses allowed to obtain products with a higher
yield and in shorter time. Compounds 2 and 5 are not
cytotoxic, as they do not exert adverse effects on the
cell cycle of the human MCF7 cell line. The com-
pounds tested are potentially of higher therapeutical
value in anti-Pseudomonas antibiotic treatment than
commercially available specifics since they show a
high level of specificity against the Pseudomonas
strains and a lower cytotoxicity than levofloxacin
with the MTT test in the MCF7 cell line. The prob-
lem is their poor solubility in water. Perhaps an
appropriate solvent composition or other additives
would allow the use of the presented compounds in
medicine.
REFERENCES
1. PorÍba K., Wietrzyk J., Opolski A.: Acta Pol.
Pharm. Drug Res. 60, 293 (2003).
2. PorÍba K., Wietrzyk J.: Adv. Clin. Exp. Med.
21, 5, 563 (2012). 
3. PorÍba K., Pawlik K., Rembacz K.P., D≥ugosz
A.: Pat. Pol. 402290 (2012).
4. Hanan E.J., Fucini R.V., Romanowski M.J.,
Elling R.A., Lew W. et al.: Bioorg. Med. Chem.
Lett. 18, 5186 (2008).
5. Zask A., Gu Y., Albright J.D., Du X., Hogan M.
et al.: Bioorg. Med. Chem. Lett. 13, 1487
(2003).
6. Bharate S.B., Mahajan T.R., Gole J.R., Nambiar
M., Matan T.T. et al.: Bioorg. Med. Chem. 16,
7167 (2008).
7. Su·rez M., Verdecia Y., Ochoa E., Salfran E.,
Moran L. et al.: Eur. J. Org. Chem. 2000, 2079
(2000).
8. Kidwai M., Negi M.: Monatsh. Chem. 128, 85
(1997).
9. Suzuki M., Iwasaki H., Fujikawa Y., Sakashita
M., Kitahara M., Sakoda R.: Bioorg. Med.
Chem. Lett. 11, 1285 (2001).
10. Tatee T., Narita K., Kurashige S., Ito S.,
Miyazaki H. et al.: Chem. Pharm. Bull. 35,
3676 (1987).
11. Tabrizi M.A., Baraldi P.G., Saponaro G.,
Moorman A.R., Romagnoli R. et al.: J. Med.
Chem. 56, 1098 (2013).
12. Qin J., Dhongi P., Huang X., Mandal M., Zhao
Z. et al.: Bioorg. Med. Chem. Lett. 21, 664
(2001).
13. Chiarino D., Napoletano M., Sala A.: J.
Heterocyclic Chem. 25, 1, 231 (1988)
Synthesis and antibacterial activity of new sulfonamide... 735
14. Owa T., Yoshino H., Okauchi T., Yoshimatsu
K., Ozawa Y. et al.: J. Med. Chem. 42, 3789
(1999).
15. Owa T., Yokoi A., Yoazaki K., Yoshimatsu K.,
Yamori T., Nagasu T.: J. Med. Chem. 45, 4913
(2002).
16. Mohan R., Banerjee M., Ray A., Manna T.,
Wilson L. et al.: Biochemistry 45, 5440 (2006).
17. Procopiou P.A., Barrett J.W., Barton N.P., Begg
M., Clapham D. et al.: J. Med. Chem. 56, 1948
(2013).
18. Lee H-Y., Pan S-L., Su M-Ch., Liu Y-M., Kuo
Ch-Ch. et al.: J. Med. Chem. 56, 8008 (2013).
19. Galiana-Rosello C., Bilbao-Ramos P., Dea-
Ayuela M.A., RolÛn M., Vega C. et al.: J. Med.
Chem. 56, 8984 (2013).
20. Kechea A.P., Hatnapurea G.D., Talec R.H.,
Rodgec A.H., Birajdara S.S., Kamble V.M.:
Bioorg. Med. Chem. Lett. 3445 (2012).
21. Tang Y., Lu D., Chen Z., Hu Ch., Yang Y. et
al.: Bioorg. Med. Lett. 23, 2313 (2013).
22. Hˆhn H., Polacek I., Schulze E.: J. Med. Chem.
16, 12, 1340 (1973).
23. Davie B.J., Christopoulos A., Scammells P.J.:
Chem.Neurosci. 1026 (2013).
24. Wilkinson B.L., Bornaghi L.F., Wright A.D.,
Houston T.A., Poulsen S.A.: Bioorg. Med.
Chem. Lett. 17, 1355 (2007).
25. Weidel E., de Jong J.. Brengel C., Storz M.P.,
Braunshausen A. et al.: J. Med. Chem. 56, 6146
(2013).
26. Nadigar M.R., Sreenivasa S., Manojkumar
K.E., Rao T.M.Ch.: J. App. Chem. 2, 722
(2013).
27. Ozawa Y., Kusano K., Owa T., Yokoi A.,
Asada M, Yoshimatsu K.: Cancer Chemother.
Pharmacol. 69, 1353 (2012).
28. Fox E., Maris J.M., Cohn S.L., Goodspeed W.,
Goodwin A. et al.: Cancer Chemother.
Pharmacol. 66, 4, 737 (2010).
29. Twenty-Second Informational Supplement.
CLSI document M100-S22.: Clinical and
Laboratory Standards Institute, Wayne PA
2012. 
30. Palomino J.-C., Martin A., Camacho M., Guerra
H., Swings J., Portaels F.: Antimicrob. Agents
Chemother. 46, 272 (2002).
Received: 9. 05. 2014
